Recent 8-K filings for LFCR

• May 06, 2026 23:59 UTC earnings materiality 0.72 negative item 2.02item 7.01item 9.01

  Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance

  Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.

• Mar 16, 2026 23:59 UTC earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M

  Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.

• Nov 06, 2025 23:59 UTC earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M

  Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.

• Aug 18, 2025 23:59 UTC other_material materiality 0.60 negative item 4.01item 9.01

  Lifecore Biomedical dismisses BDO and appoints KPMG as new independent auditor

  Audit Committee approved appointment of KPMG on August 12, 2025 as independent registered public accounting firm for transition period ending December 31, 2025.

• Aug 07, 2025 23:59 UTC earnings materiality 0.80 negative item 2.02item 9.01

  Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M

  Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.

• Apr 03, 2025 23:59 UTC earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M

  Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.50 · Most common event other_material

2 positive 3 negative 10 neutral

source · LFCR on sec.gov